Parc: A cytoplasmic anchor for p53

Cell

Volumn 112, Issue 1, 2003, Pages 29-40

  Nikolaev, Anatoly Y ^a   Li, Muyang ^a   Puskas, Norbert ^a   Qin, Jun ^b   Gu, Wei ^a  

^a The New York Presbyterian Hospital   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOPLASM PROTEIN; LIGASE; PROTEIN P53; PROTEIN PARC; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; CELL ACTIVATION; CELL LINE; CELLULAR DISTRIBUTION; CYTOPLASM; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; NEUROBLASTOMA CELL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN SECRETION; REVIEW; STRESS;

EID: 0037428078     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(02)01255-2     Document Type: Article

References (47)

1. Abou Elela S., Nazar R.N. The ribosomal 5.8S RNA as a target site for p53 protein in cell differentiation and oncogenesis. Cancer Lett. 117:1997;23-28.
2. Bosari S., Viale G., Roncalli M., Graziani D., Borsani G., Lee A.K., Coggi G. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am. J. Pathol. 147:1995;790-798.
3. Boyd S.D., Tsai K.Y., Jacks T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:2000;563-568.
4. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1983;1475-1489.
5. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498.
6. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1:1992;45-49.
7. Fontoura B.M., Atienza C.A., Sorokina E.A., Morimoto T., Carroll R.B. Cytoplasmic p53 polypeptide is associated with ribosomes. Mol. Cell. Biol. 17:1997;3146-3154.
8. Freedman D.A., Levine A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:1998;7288-7293.
9. Gannon J.V., Lane D.P. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature. 349:1991;802-806.
10. Geyer R.K., Yu Z.K., Maki C.G. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2:2000;569-573.
11. Giannakakou P., Sackett D.L., Ward Y., Webster K.R., Blagosklonny M.V., Fojo T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat. Cell Biol. 2:2000;709-717.
12. Gu J., Nie L., Wiederschain D., Yuan Z.-M. Identification of p53 sequence elements that are required for Mdm2-mediated nuclear export. Mol. Cell. Biol. 21:2001;8533-8546.
13. Gu W., Malik S., Ito M., Yuan C.X., Fondell J.D., Zhang X., Martinez E., Qin J., Roeder R.G. A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol. Cell. 3:1999;97-108.
14. Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2:2000;730-736.
15. Hollstein M., Hergenhahn M., Yang Q., Bartsch H., Wang Z.Q., Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res. 431:1999;199-209.
16. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
17. Imai Y., Soda M., Hatakeyama S., Akagi T., Hashikawa T., Nakayama K.I., Takahashi R. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell. 10:2002;55-67.
18. Jimenez G.S., Khan S.H., Stommel J.M., Wahl G.M. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene. 18:1999;7656-7665.
19. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608.
20. Klotzsche O., Etzrodt D., Hohenberg H., Bohn W., Deppert W. Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (vimentin) scaffold. Oncogene. 16:1998;3423-3434.
21. Lai Z., Ferry K.V., Diamond M.A., Wee K.E., Kim Y.B., Ma J., Yang T., Benfield P.A., Copeland R.A., Auger K.R. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J. Biol. Chem. 276:2001;31357-31367.
22. Li M., Chen D., Shiloh A., Luo J., Nikolaev A.Y., Qin J., Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 416:2002;648-653. a.
23. Li M., Luo J., Brooks C.L., Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277:2002;50607-50611. b Published online November 5, 2002. 10.1074/jbc.C200578200.
24. Liang S.H., Hong D., Clarke M.F. Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. J. Biol. Chem. 273:1998;19817-19821.
25. Lohrum M.A., Woods D.B., Ludwig R.L., Balint E., Vousden K.H. C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell. Biol. 21:2001;8521-8532.
26. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 408:2000;377-381.
27. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107:2001;137-148.
28. Metcalfe S., Weeds A., Okorokov A.L., Milner J., Cockman M., Pope B. Wild-type p53 protein shows calcium-dependent binding to F-actin. Oncogene. 18:1999;2351-2355.
29. Middeler G., Zerf K., Jenovai S., Thulig A., Tschodrich-Rotter M., Kubitscheck U., Peters R. The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene. 14:1997;1407-1417.
30. Moll U.M., Riou G., Levine A.J. Two distinct mechanisms alter p53 in breast cancer. mutation and nuclear exclusion Proc. Natl. Acad. Sci. USA. 89:1992;7262-7266.
31. Moll U.M., LaQuaglia M., Benard J., Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA. 92:1995;4407-4411.
32. Moll U.M., Ostermeyer A.G., Haladay R., Winkfield B., Frazier M., Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16:1996;1126-1137.
33. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:2001;503-533.
34. Schlamp C.L., Poulsen G.L., Nork T.M., Nickells R.W. Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells. J. Natl. Cancer Inst. 89:1997;1530-1536.
35. Sengupta S., Vonesch J.L., Waltzinger C., Zheng H., Wasylyk B. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J. 19:2000;6051-6064.
36. Sharpless N.E., DePinho R.A. p53. Good cop/bad cop. Cell. 110:2002;9-12.
37. Shaulsky G., Goldfinger N., Ben-Ze'ev A., Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol. 10:1990;6565-6577.
38. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25:2000;302-305.
39. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain. regulation of subcellular localization and p53 activity by NES masking EMBO J. 18:1999;1660-1672.
40. Sun X.F., Carstensen J.M., Zhang H., Stal O., Wingren S., Hatschek T., Nordenskjold B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet. 340:1992;1369-1373.
41. Tao W., Levine A.J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA. 96:1999;3077-3080.
42. Ueda H., Ullrich S.J., Gangemi J.D., Kappel C.A., Ngo L., Feitelson M.A., Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 9:1995;41-47.
43. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
44. Vousden K.H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta. 1602:2002;47-59.
45. Xirodimas D.P., Stephen C.W., Lane D.P. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp. Cell Res. 270:2001;66-77.
46. Zaika A., Marchenko N., Moll U.M. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J. Biol. Chem. 274:1999;27474-27480.
47. Zhang Y., Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science. 292:2001;1910-1915.